Patents by Inventor Carol A. Feghali-Bostwick

Carol A. Feghali-Bostwick has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Use of endostatin peptides for the treatment of fibrosis
    Patent number: 8716232
    Abstract: C-terminal endostatin polypeptides are disclosed herein. Polynucleotides encoding these polypeptide, host cells transformed with the polynucleotides, and methods of using these polypeptides and polynucleotides are disclosed. Uses of these polypeptide, polynucleotides and expression vectors include the treatment of fibrosis in a subject. Thus, methods are provided for treating fibrosis, including fibrosis of the skin and/or the lung.
    Type: Grant
    Filed: July 10, 2013
    Date of Patent: May 6, 2014
    Assignee: University of Pittsburgh— of the Commonwealth System of Higher Education
    Inventors: Carol A. Feghali-Bostwick, Yukie Yamaguchi
  • USE OF ENDOSTATIN PEPTIDES FOR THE TREATMENT OF FIBROSIS
    Publication number: 20130316959
    Abstract: C-terminal endostatin polypeptides are disclosed herein. Polynucleotides encoding these polypeptide, host cells transformed with the polynucleotides, and methods of using these polypeptides and polynucleotides are disclosed. Uses of these polypeptide, polynucleotides and expression vectors include the treatment of fibrosis in a subject. Thus, methods are provided for treating fibrosis, including fibrosis of the skin and/or the lung.
    Type: Application
    Filed: July 10, 2013
    Publication date: November 28, 2013
    Applicant: University of Pittsburgh - Of the Commonwealth System of Higher Education
    Inventors: Carol A. Feghali-Bostwick, Yukie Yamaguchi
  • Use of endostatin peptides for the treatment of fibrosis
    Patent number: 8507441
    Abstract: C-terminal endostatin polypeptides are disclosed herein. In some embodiments, these polypeptides include or consist of (1) at least at least 40 consecutive amino acids of the amino acid sequence set forth as amino acids 133-180 of SEQ ID NO: 2, SEQ ID NO: 13 or SEQ ID NO: 4; (2) at least 40 consecutive amino acids of the amino acid sequence set forth as amino acids 133-180 of SEQ ID NO: 2, SEQ ID NO: 13 or SEQ ID NO: 4 with at most 5 amino acid substitutions, (3) the amino acid sequence set forth as amino acids 133-180 of SEQ ID NO: 2, SEQ ID NO: 13 or SEQ ID NO: 4; or (4) the amino acid sequence set forth as amino acids 133-180 of SEQ ID NO: 2, SEQ ID NO: 13 or SEQ ID NO: 4 with at most 5 amino acid substitutions; wherein the polypeptide has anti-fibrotic activity and wherein the polypeptide does not comprise amino acids 1-92 of SEQ ID NO: 2, SEQ ID NO: 13 or SEQ ID NO: 4.
    Type: Grant
    Filed: October 22, 2010
    Date of Patent: August 13, 2013
    Assignee: University of Pittsburgh—Of the Commonwealth Systems of Higher Education
    Inventors: Carol A. Feghali-Bostwick, Yukie Yamaguchi
  • USE OF ENDOSTATIN PEPTIDES FOR THE TREATMENT OF FIBROSIS
    Publication number: 20120220536
    Abstract: C-terminal endostatin polypeptides are disclosed herein. In some embodiments, these polypeptides include or consist of (1) at least at least 40 consecutive amino acids of the amino acid sequence set forth as amino acids 133-180 of SEQ ID NO: 2, SEQ ID NO: 13 or SEQ ID NO: 4; (2) at least 40 consecutive amino acids of the amino acid sequence set forth as amino acids 133-180 of SEQ ID NO: 2, SEQ ID NO: 13 or SEQ ID NO: 4 with at most 5 amino acid substitutions, (3) the amino acid sequence set forth as amino acids 133-180 of SEQ ID NO: 2, SEQ ID NO: 13 or SEQ ID NO: 4; or (4) the amino acid sequence set forth as amino acids 133-180 of SEQ ID NO: 2, SEQ ID NO: 13 or SEQ ID NO: 4 with at most 5 amino acid substitutions; wherein the polypeptide has anti-fibrotic activity and wherein the polypeptide does not comprise amino acids 1-92 of SEQ ID NO: 2, SEQ ID NO: 13 or SEQ ID NO: 4.
    Type: Application
    Filed: October 22, 2010
    Publication date: August 30, 2012
    Inventors: Carol A. Feghali-Bostwick, Yukie Yamaguchi
  • ESTROGEN ANTAGONISTS AS TREATMENTS FOR SCLEROSING DISORDERS
    Publication number: 20120135971
    Abstract: The present invention relates to methods and compositions for treating a subject suffering from a sclerosing disorder, comprising administering, to the subject, an effective amount of an estrogen receptor antagonist (“ERANT”), wherein said ERANT has essentially no estrogen receptor agonist activity under physiologic conditions.
    Type: Application
    Filed: January 18, 2012
    Publication date: May 31, 2012
    Inventors: Carol A. Feghali-Bostwick, Pamela Anne Hershberger